ForSight Robotics completed a $125 million Series B round to fund the next growth phase for the ORYOM Platform, what the company is calling the world’s first robotic surgery platform for cataract and other eye diseases.
The platform is designed to enhance surgical precision, increase patient access to treatment, and decrease the physical burden on surgeons.
The ORYOM Platform uses AI-based algorithms, advanced computer vision, and micromechanics to deliver unprecedented dexterity and maneuverability while providing surgeons with an improved ergonomic experience. The ORYOM Platform can reach any point within the human eye, allowing surgeons to navigate complex angles and ensuring access to both anterior and posterior segments.
As the company scales, the founding team has convened a strategic advisory board of the preeminent leaders in surgical robotics, including Dr. Fred Moll, the founder of Intuitive Surgical and the da Vinci surgical system, who is widely regarded as the “father of surgical robotics,” and Rony Abovitz, the founder of MAKO Surgical Corp. Moll recently joined the company's board of directors.
